Large Molecule Drug Substance Pandemic Complications

ISR asked respondents to its annual biologic drug substance benchmarking surveys over the past two years whether they encountered pandemic related complications with their outsourced manufacturing. Interestingly, it was more common for large molecule drug substance outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020. To learn more about large molecule drug substance manufacturers’ performance during the pandemic, follow the link to the Biologic API CMO Benchmarking report preview.